Basit öğe kaydını göster

dc.contributor.authorİlter, Metehan
dc.contributor.authorKaşmer, Ramazan
dc.contributor.authorJalalypour, Farzaneh
dc.contributor.authorAtılgan, Canan
dc.contributor.authorTopçu, Ozan
dc.contributor.authorKarakaş, Nihal
dc.contributor.authorŞensoy, Özge
dc.date.accessioned2023-01-09T06:48:07Z
dc.date.available2023-01-09T06:48:07Z
dc.date.issued2022en_US
dc.identifier.citationİlter, M., Kaşmer, R., Jalalypour, F., Atılgan, C., Topçu, O., Karakaş, N. ... Şensoy, Ö. (2022). Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS. eLife, 11. https://dx.doi.org/10.7554/eLife.79747en_US
dc.identifier.issn2050-084X
dc.identifier.urihttps://dx.doi.org/10.7554/eLife.79747
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10260
dc.description.abstractUndruggability of RAS proteins has necessitated alternative strategies for the development of effective inhibitors. In this respect, phosphorylation has recently come into prominence as this reversible post-translational modification attenuates sensitivity of RAS towards RAF. As such, in this study, we set out to unveil the impact of phosphorylation on dynamics of HRASWT and aim to invoke similar behavior in HRASG12D mutant by means of small therapeutic molecules. To this end, we performed molecular dynamics (MD) simulations using phosphorylated HRAS and showed that phosphorylation of Y32 distorted Switch I, hence the RAS/RAF interface. Consequently, we targeted Switch I in HRASG12D by means of approved therapeutic molecules and showed that the ligands enabled detachment of Switch I from the nucleotide-binding pocket. Moreover, we demonstrated that displacement of Switch I from the nucleotide-binding pocket was energetically more favorable in the presence of the ligand. Importantly, we verified computational findings in vitro where HRASG12D/RAF interaction was prevented by the ligand in HEK293T cells that expressed HRASG12D mutant protein. Therefore, these findings suggest that targeting Switch I, hence making Y32 accessible might open up new avenues in future drug discovery strategies that target mutant RAS proteins.en_US
dc.language.isoengen_US
dc.publisherNLM (Medline)en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectEukaryotic Expression Plasmiden_US
dc.subjectHek-293t -Hras-G12den_US
dc.subjectHek-293t -Hras-Wten_US
dc.subjectMolecular Biophysicsen_US
dc.subjectStructural Biologyen_US
dc.titleInhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RASen_US
dc.typearticleen_US
dc.relation.ispartofeLifeen_US
dc.departmentİstanbul Medipol Üniversitesi, Sağlık Bilimleri Enstitüsü, Tıbbi Biyoloji ve Genetik Ana Bilim Dalıen_US
dc.departmentİstanbul Medipol Üniversitesi, Rektörlük, Sağlık Bilim ve Teknolojileri Araştırma Enstitüsüen_US
dc.departmentİstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Biyoloji Ana Bilim Dalıen_US
dc.departmentİstanbul Medipol Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Bilgisayar Mühendisliği Bölümüen_US
dc.departmentİstanbul Medipol Üniversitesi, Rektörlük, Rejeneratif ve Restoratif Tıp Araştırmaları Merkezi (REMER)en_US
dc.identifier.volume11en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.7554/eLife.79747en_US
dc.institutionauthorİlter, Metehan
dc.institutionauthorKaşmer, Ramazan
dc.institutionauthorTopçu, Ozan
dc.institutionauthorKarakaş, Nihal
dc.institutionauthorŞensoy, Özge
dc.identifier.wosqualityQ1en_US
dc.identifier.wos000931390400001en_US
dc.identifier.scopus2-s2.0-85144588808en_US
dc.identifier.pmid36458814en_US
dc.identifier.scopusqualityQ1en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

info:eu-repo/semantics/openAccess
Aksi belirtilmediği sürece bu öğenin lisansı: info:eu-repo/semantics/openAccess